Expert Guidance for Optimizing Immune Checkpoint Inhibitor Therapy for Kidney and Bladder Cancer

The goal of this activity is to increase participants’ ability to use immune checkpoint inhibitors for management of individual patients with urothelial cell and renal cell carcinoma to improve clinical outcomes and quality of life.

Target Audience

This activity is intended for oncologists and other healthcare professionals, including nurses, nurse practitioners, physician assistants, and pharmacists, who provide medical care for patients with urothelial cell and renal cell carcinoma.

Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca and Genentech and independent medical education grants from Bristol-Myers Squibb and Merck Co., Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 0.93 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
04/28/2017
Course expires: 
03/01/2018
Cost:
$0.00

Presenters

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

M. Dror Michaelson, MD, PhD
Clinical Director, Genitourinary Cancer Center
Associate Professor of Medicine
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Contributing Faculty

Neeraj Agarwal, MD
Associate Professor of Medicine
Division of Medical Oncology
Director, GU Medical Oncology
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

Timothy M. Kuzel, MD, FACP
Chief, Division of Hematology/Oncology and Cell Therapy
Professor of Medicine
Rush Medical College
Chicago, Illinois

Lance C. Pagliaro, MD
Professor of Oncology
Division of Medical Oncology
Department of Oncology
Mayo Clinic College of Medicine
Rochester, Minnesota

Brian Rini, MD, FACP
Staff Physician
Department of Solid Tumor Oncology and Urology
Cleveland Clinic Taussig Cancer Institute
Professor of Medicine
CCR/CWRU Lerner College of Medicine
Cleveland, Ohio

Disclosure of Relevant Financial Relationships

All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics.

The faculty and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Neeraj Agrawal, MD, has disclosed that he has served on advisory boards for Eisai, EMD Serono, Exelixis, Merck, Novartis, and Pfizer.

Timothy M. Kuzel, MD, FACP, has disclosed that he has received consulting fees from Spectrum; has received honoraria from Bristol-Myers Squibb, Genentech, and sanofi-aventis; has received funds for research support from Bristol-Myers Squibb and Eisai; has served on advisory boards for Celgene, Genentech, Eisai, and Exelixis; and has served on drug monitoring committees for Amgen, Argos, and Merck.

M. Dror Michaelson, MD, PhD, has disclosed that he has received funds for research support from Argos and Eisai and has served on advisory boards for Exelixis, Novartis, and Pfizer.

Lance C. Pagliaro, MD, has no real or apparent conflicts of interest to report.

Elizabeth R. Plimack, MD, MS, has disclosed that she has received consulting fees from Lilly, Pfizer, and SynerGene; has received honorarium from Roche; has received funds for research support from Acceleron, AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Novartis, Peloton Therapeutics, and Pfizer; and has served as a scientific advisor for AstraZeneca, Bristol-Myers Squibb, Exelixis, Genentech, and Novartis.

Brian Rini, MD, FACP, has disclosed that he has received consulting fees from Merck and Pfizer and funds for research support from Bristol-Myers Squibb, Genentech, Merck, and Pfizer.

The activity planning staff listed below has no relevant financial relationships to disclose:

CCO: Kristen Rosenthal, PhD; Rachael M. Andrie, PhD; Krista Marcello; Kevin Obholz, PhD

NCCN: Kristina M. Gregory, RN, MSN, OCN; Karen Kanefield; Kristin Kline Hasson; Joan S. McClure, MS; Deborah Moonan, RN, BSN; Lisa Perfidio; Kathy Smith

The NCCN clinical information team listed below, who have reviewed content, have no relevant financial relationships to disclose:

Rashmi Kumar, PhD

The NCCN Clinical Information staff listed below, who has reviewed content, discloses the following relevant financial relationships:

Courtney Smith, PhD, Johnson & Johnson, Opko Health Inc: Equity Interest/Stock Options

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of NCCN and Clinical Care Options, LLC. NCCN is accredited by the ACCME to provide continuing medical education for physicians.

NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.93 contact hours.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.01 CEUs) of continuing education credit. UAN: 0836-9999-17-025-H01-P

Available Credit

  • 1.00 ACPE contact hours
  • 0.93 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Gain insight on the mechanism of action and rationale for using immune checkpoint inhibitors to treat patients with advanced bladder cancer and renal cell carcinoma
  • Evaluate the available data and recommendations in the NCCN Guidelines® on different checkpoint inhibitors to guide therapy decisions for patients with bladder cancer and renal cell carcinoma
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors

Accreditation Period

Course opens: 
04/28/2017
Course expires: 
03/01/2018

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: